Xin Lang Cai Jing·2026-03-27 06:53Core Viewpoint - Tiger Med has seen a 5% increase in stock price, reaching 53.32 CNY per share, with a total market capitalization of 45.91 billion CNY, indicating a positive market sentiment towards the company [1][4]. Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1][4]. - The main business activities include I to IV phase clinical trial technical services, data management and statistical analysis, registration application, on-site clinical trial services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][4]. - The revenue composition of the company is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [1][4]. Fund Holdings - One fund under Huatai Asset Management holds a significant position in Tiger Med. The Huatai Zijin Innovation Pioneer Mixed Fund (LOF) C (501202) reduced its holdings by 32,100 shares in the fourth quarter, now holding 175,300 shares, which represents 4.83% of the fund's net value, making it the fourth-largest holding [2][5]. - The fund has reported a floating profit of approximately 445,300 CNY today and a total of 568,000 CNY during the three-day increase [2][5]. - The Huatai Zijin Innovation Pioneer Mixed Fund (LOF) C was established on July 17, 2020, with a current size of 189 million CNY. Year-to-date, it has experienced a loss of 2.41%, ranking 6181 out of 8898 in its category, while it has achieved a return of 27.77% over the past year, ranking 2487 out of 8181 [2][5].